SEC Form 4 · accession 0000884731-17-000018
ARIAD PHARMACEUTICALS INC · ARIA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel M Bollag
Officer — Sr. VP, Reg. Affairs & Quality
Period of report
Jan 31, 2017
Accepted (ET)
Feb 2, 2017 · 4:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000884731
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 31, 2017 | M | 29,333 | $0.00 | A | 141,019 | D | |
| Common StockF3 | Jan 31, 2017 | F | 14,667 | $23.8149 | D | 126,352 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4,F5 | $0.00 | Jan 31, 2017 | M | 29,333 | D | — | — | Common Stock | 29,333 | 0 | D |
Explanation of responses
- F1Shares were acquired upon the vesting of a Restricted Stock Unit previously granted on January 31, 2014.
- F2Shares were sold to satisfy the Company's tax withholding obligations pursuant to a Rule 10b5-1 plan adopted on June 15, 2016.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.795 to $23.83, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
- F4Restricted Stock Units vest as approximately to one-third of the award on each of January 31, 2015, January 31, 2016 and January 31, 2017.
- F5N/A